Press Release NeuroDex Awarded Target ALS Biomarker Consortia Grant to Drive Advancements in ALS Research Natick, Massachusetts (November 6, 2024) – NeuroDex Inc. (“NeuroDex” or the “Company”) proudly announces its selection as a recipient of the Target ALS Biomarker Consortia Grant. This significant funding will bolster NeuroDex’s efforts to pioneer novel blood-based biomarkers, aiming to…
Showcasing Pioneering Diagnostic Technologies We proudly announce that Neurodex will play a significant role at the forthcoming Bio-Neuroscience Conference, highlighting our innovative diagnostic technologies for neurodegenerative diseases. Oded Biran, our distinguished SEO, will present our leading-edge work in developing blood-based biomarkers and leveraging cell-specific extracellular vesicles (exosomes) for precise diagnostics. About Our Innovations Neurodex is…
In a remarkable stride towards advancing healthcare, Canadian innovators have unveiled a groundbreaking artificial intelligence (AI) program to transform the early detection of Amyotrophic Lateral Sclerosis (ALS). Mitsubishi Tanabe Pharma Canada (MTP-CA) takes immense pride in supporting this revolutionary AI technology, which harnesses the power of AI to scrutinize de-identified electronic medical records (EMRs). This…